OHSU in the news

'We need to see the data': FDA's Xeljanz safety warning stirs concerns for JAK inhibitors

Healio February 16, 2021
In a story about interim and preliminary results of a safety clinical trial prompting the FDA to warning the rheumatoid arthritis drug tofacitinib carrying an increased risk of heart issues and cancer among older patients, Kevin Winthrop, M.D., M.P.H., says “To be honest, it’s hard to know what to think. We need to see the data in the analysis.”

Biotech sector blooms

Oregon Business February 16, 2021
A feature about the growth of the biotech sector in Oregon reference's OHSU's collaboration with NanoString Technologies to develop a new breast cancer detection technology.
See more stories